Testing Vivus' Staying Power
Vivus' first-year sales of its impotence drug surpassed even its most optimistic projections. But that very success led to problems, most notably manufacturing capacity shortfalls, that threaten not just future US growth, but the drug's European launch, just when Vivus is bracing for Pfizer's market entry.
You may also be interested in...
SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
Industry group AdvaMed says its Indian code on interactions between medtech companies and health care professionals is a first for the country.